IP Library Granted Patent US 9,409,967
Granted Patent B2
US 9,409,967 · App. 14/348,634 · Granted Aug 9, 2016

Method for purification of cleaved pro-insulin

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,409,967
App. No.
14/348,634
Granted
Aug 9, 2016
Kind
B2
Abstract

The present invention is within the field of biomolecule purification. More closely the invention relates to chromatographic purification of insulin using a specific kind of shell beads having an inner core and an outer functionalized layer. The method enables purification at high flow rates and high purity, over 90%.

Claims (17)

1. A method for purification of insulin from pro-insulin comprising the following steps:

loading a sample of cleaved pro-insulin onto a chromatography medium comprising porous shell beads having an inner core and an outer layer, wherein the inner core is non-functionalized while the outer layer is functionalized with ion exchange ligands;

adsorbing insulin on the ion exchange ligands; and

eluting insulin from the chromatography medium at a flow rate of 100-1000 cm/h, wherein the eluted insulin has a purity of more than 85%.

2. The method of claim 1 , wherein the porous shell beads are 20-100 μm in diameter.

3. The method of claim 1 , wherein the porous shell beads are 40-80 μm in diameter.

4. The method of claim 1 , wherein the functionalized layer of the porous shell beads comprises a 3-9 μm thick layer.

5. The method of claim 1 , wherein the functionalized layer of the porous shell beads comprises a 5-7 μm thick layer.

6. The method of claim 1 , wherein the ion exchange ligand is a strong cation exchange group selected from the group consisting of sulphonate (SO 3 − ), sulphate (—OSO 3 − ), phosphate (—OPO 3 2− ), and phosphonate (PO 3 2− ).

7. The method of claim 1 , wherein the inner core is filled with a polar polymer selected from the group consisting of agarose, dextran, cellulose, starch, and pullulan.

8. The method of claim 1 , wherein the pro-insulin is produced from bacteria.

9. The method of claim 1 , wherein the eluted insulin has a purity of more than 90%.

10. The method of claim 1 , wherein the flow rate is 300-600 cm/h.

11. The method of claim 1 , wherein the inner core is inactive.

12. The method of claim 1 , wherein the inner core is empty.

13. The method of claim 1 , wherein the porous shell beads are 60-80 μm in diameter.

14. The method of claim 1 , wherein the inner core is filled with a synthetic polymer selected from the group consisting of polyacrylic amide, polymethacrylic amide, and poly(hydroxyalkylacrylates).

Assignments (3)
CHANGE OF NAME Recorded Jan 24, 2022
From: GE HEALTHCARE BIOPROCESS R&D AB
To: CYTIVA BIOPROCESS R & D AB
Reel/Frame 058826/0901 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2016
From: GE HEALTHCARE BIO-SCIENCES AB
To: GE HEALTHCARE BIOPROCESS R&D AB
Reel/Frame 038811/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2014
From: BREKKAN, EGGERT; ERIKSSON, KJELL; JOHANSSON, BO-LENNART; SHANAGAR, JAMIL
To: GE HEALTHCARE BIO-SCIENCES AB
Reel/Frame 032558/0080 →